Author:
Abrecht Stefan,Trussardi René,Rimmler Gösta,Oberhauser Thomas,Mair Hans-Jürgen,Karpf Martin,Fischer Rolf,Estermann Heinrich,Federspiel Muriel Cordon,Zutter Ulrich
Abstract
The clinical development of the first orally available neuraminidase inhibitor prodrug oseltamivir phosphate (Tamiflu™) proceeded very fast. In order to support this program an unprecedented team effort in chemical process research, development, piloting, production
and analytics took place, which allowed the successful launch of Tamiflu™ in 1999, only two and a half years after it was licensed from Gilead Sciences. This article describes selected aspects of the commercially used synthesis route and a brief summary of alternative syntheses
devised by Roche chemists.
Subject
General Medicine,General Chemistry
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献